Live donor renal allograft in end-stage renal failure patients from immunoglobulin A nephropathy

YuSeun Kim, Jang Il Moon, Hyeon Joo Jeong, Myoung Soo Kim, Soon Il Kim, Kyu Hun Choi, Ho Yung Lee, Dae Suk Han, Kiil Park

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Background. The purpose of this study was to attempt to resolve two important issues, i.e. to determine (1) whether the course of recurrent immunoglobulin A nephropathy (IgAN) is benign, and (2) whether it is advisable to use a related donor. Methods. We evaluated the long-term outcome, in terms of recurrence and graft survival, after live related or unrelated donor renal transplantation, and assessed the validity of the use of related donors in 90 grafts in 89 IgAN patients. Results. Ten-year graft survival for IgAN patients was 66%, compared with 84% for 107 reference recipients who had other kinds of glomerulonephritis (GN), and with 69% in 90 other recipients who had non-GN renal failure (P=0.27). In 43 grafts, 54 event graft biopsies were performed, documenting the presence of mesangial IgA deposits in 19 of those grafts. In eight grafts, lesions were accompanied by chronic rejection (CR). Ten-year cumulative recurrence was 44%. Ten grafts were lost: by CR (n=3) or acute rejection (n=1) in 24 recurrence-free recipients, by CR (n=2) or recurrence (n=2) in 19 recurrent patients, and by patient death (n=2) in 46 patients devoid of graft biopsy. We found no difference in 1O-year graft survival between the recurrent and recurrence-free patients (63% vs. 74%, P=0.98), or the proportion of related donors (68% vs. 83%, P=0.25). The presence or matching of HLA B12, B35, or DR4 did not affect the recurrence. Conclusions. Recurrence increased to 44% with longer follow-up, but this did not limit the graft outcome. Recurrence was not affected by the kind of live donor. We conclude that live related or unrelated kidneys should be offered to IgAN patients.

Original languageEnglish
Pages (from-to)233-238
Number of pages6
JournalTransplantation
Volume71
Issue number2
DOIs
Publication statusPublished - 2001 Jan 27

Fingerprint

IGA Glomerulonephritis
Chronic Kidney Failure
Allografts
Tissue Donors
Transplants
Kidney
Recurrence
Graft Survival
HLA-B35 Antigen
HLA-DR4 Antigen
Biopsy
Unrelated Donors
Glomerulonephritis
Kidney Transplantation
Immunoglobulin A
Renal Insufficiency

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

Kim, YuSeun ; Moon, Jang Il ; Jeong, Hyeon Joo ; Kim, Myoung Soo ; Kim, Soon Il ; Choi, Kyu Hun ; Lee, Ho Yung ; Han, Dae Suk ; Park, Kiil. / Live donor renal allograft in end-stage renal failure patients from immunoglobulin A nephropathy. In: Transplantation. 2001 ; Vol. 71, No. 2. pp. 233-238.
@article{4fbf7b152c6d4aaaa395bf9f83852201,
title = "Live donor renal allograft in end-stage renal failure patients from immunoglobulin A nephropathy",
abstract = "Background. The purpose of this study was to attempt to resolve two important issues, i.e. to determine (1) whether the course of recurrent immunoglobulin A nephropathy (IgAN) is benign, and (2) whether it is advisable to use a related donor. Methods. We evaluated the long-term outcome, in terms of recurrence and graft survival, after live related or unrelated donor renal transplantation, and assessed the validity of the use of related donors in 90 grafts in 89 IgAN patients. Results. Ten-year graft survival for IgAN patients was 66{\%}, compared with 84{\%} for 107 reference recipients who had other kinds of glomerulonephritis (GN), and with 69{\%} in 90 other recipients who had non-GN renal failure (P=0.27). In 43 grafts, 54 event graft biopsies were performed, documenting the presence of mesangial IgA deposits in 19 of those grafts. In eight grafts, lesions were accompanied by chronic rejection (CR). Ten-year cumulative recurrence was 44{\%}. Ten grafts were lost: by CR (n=3) or acute rejection (n=1) in 24 recurrence-free recipients, by CR (n=2) or recurrence (n=2) in 19 recurrent patients, and by patient death (n=2) in 46 patients devoid of graft biopsy. We found no difference in 1O-year graft survival between the recurrent and recurrence-free patients (63{\%} vs. 74{\%}, P=0.98), or the proportion of related donors (68{\%} vs. 83{\%}, P=0.25). The presence or matching of HLA B12, B35, or DR4 did not affect the recurrence. Conclusions. Recurrence increased to 44{\%} with longer follow-up, but this did not limit the graft outcome. Recurrence was not affected by the kind of live donor. We conclude that live related or unrelated kidneys should be offered to IgAN patients.",
author = "YuSeun Kim and Moon, {Jang Il} and Jeong, {Hyeon Joo} and Kim, {Myoung Soo} and Kim, {Soon Il} and Choi, {Kyu Hun} and Lee, {Ho Yung} and Han, {Dae Suk} and Kiil Park",
year = "2001",
month = "1",
day = "27",
doi = "10.1097/00007890-200101270-00011",
language = "English",
volume = "71",
pages = "233--238",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Kim, Y, Moon, JI, Jeong, HJ, Kim, MS, Kim, SI, Choi, KH, Lee, HY, Han, DS & Park, K 2001, 'Live donor renal allograft in end-stage renal failure patients from immunoglobulin A nephropathy', Transplantation, vol. 71, no. 2, pp. 233-238. https://doi.org/10.1097/00007890-200101270-00011

Live donor renal allograft in end-stage renal failure patients from immunoglobulin A nephropathy. / Kim, YuSeun; Moon, Jang Il; Jeong, Hyeon Joo; Kim, Myoung Soo; Kim, Soon Il; Choi, Kyu Hun; Lee, Ho Yung; Han, Dae Suk; Park, Kiil.

In: Transplantation, Vol. 71, No. 2, 27.01.2001, p. 233-238.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Live donor renal allograft in end-stage renal failure patients from immunoglobulin A nephropathy

AU - Kim, YuSeun

AU - Moon, Jang Il

AU - Jeong, Hyeon Joo

AU - Kim, Myoung Soo

AU - Kim, Soon Il

AU - Choi, Kyu Hun

AU - Lee, Ho Yung

AU - Han, Dae Suk

AU - Park, Kiil

PY - 2001/1/27

Y1 - 2001/1/27

N2 - Background. The purpose of this study was to attempt to resolve two important issues, i.e. to determine (1) whether the course of recurrent immunoglobulin A nephropathy (IgAN) is benign, and (2) whether it is advisable to use a related donor. Methods. We evaluated the long-term outcome, in terms of recurrence and graft survival, after live related or unrelated donor renal transplantation, and assessed the validity of the use of related donors in 90 grafts in 89 IgAN patients. Results. Ten-year graft survival for IgAN patients was 66%, compared with 84% for 107 reference recipients who had other kinds of glomerulonephritis (GN), and with 69% in 90 other recipients who had non-GN renal failure (P=0.27). In 43 grafts, 54 event graft biopsies were performed, documenting the presence of mesangial IgA deposits in 19 of those grafts. In eight grafts, lesions were accompanied by chronic rejection (CR). Ten-year cumulative recurrence was 44%. Ten grafts were lost: by CR (n=3) or acute rejection (n=1) in 24 recurrence-free recipients, by CR (n=2) or recurrence (n=2) in 19 recurrent patients, and by patient death (n=2) in 46 patients devoid of graft biopsy. We found no difference in 1O-year graft survival between the recurrent and recurrence-free patients (63% vs. 74%, P=0.98), or the proportion of related donors (68% vs. 83%, P=0.25). The presence or matching of HLA B12, B35, or DR4 did not affect the recurrence. Conclusions. Recurrence increased to 44% with longer follow-up, but this did not limit the graft outcome. Recurrence was not affected by the kind of live donor. We conclude that live related or unrelated kidneys should be offered to IgAN patients.

AB - Background. The purpose of this study was to attempt to resolve two important issues, i.e. to determine (1) whether the course of recurrent immunoglobulin A nephropathy (IgAN) is benign, and (2) whether it is advisable to use a related donor. Methods. We evaluated the long-term outcome, in terms of recurrence and graft survival, after live related or unrelated donor renal transplantation, and assessed the validity of the use of related donors in 90 grafts in 89 IgAN patients. Results. Ten-year graft survival for IgAN patients was 66%, compared with 84% for 107 reference recipients who had other kinds of glomerulonephritis (GN), and with 69% in 90 other recipients who had non-GN renal failure (P=0.27). In 43 grafts, 54 event graft biopsies were performed, documenting the presence of mesangial IgA deposits in 19 of those grafts. In eight grafts, lesions were accompanied by chronic rejection (CR). Ten-year cumulative recurrence was 44%. Ten grafts were lost: by CR (n=3) or acute rejection (n=1) in 24 recurrence-free recipients, by CR (n=2) or recurrence (n=2) in 19 recurrent patients, and by patient death (n=2) in 46 patients devoid of graft biopsy. We found no difference in 1O-year graft survival between the recurrent and recurrence-free patients (63% vs. 74%, P=0.98), or the proportion of related donors (68% vs. 83%, P=0.25). The presence or matching of HLA B12, B35, or DR4 did not affect the recurrence. Conclusions. Recurrence increased to 44% with longer follow-up, but this did not limit the graft outcome. Recurrence was not affected by the kind of live donor. We conclude that live related or unrelated kidneys should be offered to IgAN patients.

UR - http://www.scopus.com/inward/record.url?scp=0035956736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035956736&partnerID=8YFLogxK

U2 - 10.1097/00007890-200101270-00011

DO - 10.1097/00007890-200101270-00011

M3 - Article

C2 - 11213065

AN - SCOPUS:0035956736

VL - 71

SP - 233

EP - 238

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 2

ER -